Search Results
Jul 21, 2026, 11:01 ET TYBR Health Announces $30 Million Series A Financing to Expand Access to the B3 GEL® System
of successfully partnering with entrepreneurs behind industry-leading companies, including Artelon, Cameron Health, CardiAQ, Cartiva, CV Ingenuity, Epix Therapeutics, Inari Medical, Intact Vascular, Lutonix, Neuwave Medical, Personal Genome Diagnostics, Relievant Medsystems, Sequent Medical, Topera,
More news about: TYBR Health
Mar 26, 2026, 12:51 ET MAGGIE BAIRD, SUPPORT+FEED AND WETA ANNOUNCE NEW PUBLIC MEDIA SERIES IN DEVELOPMENT: CLIMATE KITCHEN
Critic's Picks; Tapped; Get Smart with Money on Netflix; The Disruptors on Apple+; Invisible Monsters on A&E; and Alive on Epix. More information is available at
More news about: WETA
Jan 20, 2026, 08:00 ET MellingMedical Partners with Applied Medical to Offer Minimally Invasive Surgical Solutions Throughout the Federal Healthcare System
Intelligent Energy system, Kii® Access systems, Alexis® protectors and systems, GelPOINT® access platforms, and Epix® laparoscopic instruments. These technologies support multiple surgical specialties including general, bariatric, cardiac, colorectal, gynecologic,
More news about: MellingMedical
Jan 09, 2026, 13:27 ET Ventaris Surgical, Inc. Announces $30M Series A to Advance a Next-Generation System for Complete Kidney Stone Treatment
successfully partnering with entrepreneurs behind industry-leading companies, including Artelon, Cameron Health, CardiAQ, Cartiva, CV Ingenuity, CVRx, Epix Therapeutics, Inari Medical, Intact Vascular, Lutonix, Neuwave Medical, Personal Genome Diagnostics, Relievant Medsystems, Sequent Medical, Topera,
More news about: Ventaris Surgical, Inc.
Oct 09, 2025, 07:00 ET ESSA Announces Completion of Arrangement with XenoTherapeutics
FRANCISCO, Calif., USA and VANCOUVER, BC, Canada, Oct. 9, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company") today announced the completion of XenoTherapeutics' ("Xeno") previously announced acquisition of ESSA (the "Acquisition").
More news about: ESSA Pharma Inc
Oct 06, 2025, 17:14 ET ESSA Securityholders Approve Acquisition by XenoTherapeutics
SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, Oct. 6, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company") is pleased to announce that its Securityholders (as defined below) have approved the acquisition of all of the issued and
More news about: ESSA Pharma Inc
Sep 30, 2025, 16:30 ET ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order
and VANCOUVER, BC, Sept. 30, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in connection with its previously announced Business Combination Agreement with XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology
More news about: ESSA Pharma Inc.
Sep 24, 2025, 06:00 ET ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
Sept. 24, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that it has reached an agreement to amend its previously announced Business Combination Agreement (the "Amended Agreement") with XenoTherapeutics
More news about: ESSA Pharma Inc.
Sep 10, 2025, 06:00 ET Essa Pharma Inc. to Adjourn Special Meeting to September 29, 2025
Sept. 10, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that the Board of Directors of the Company has approved an adjournment of the special meeting of the holders of common shares of the
More news about: ESSA Pharma Inc.